The Cannabis Sector and Its Dot-Com Like Meltdown

Black-market vaping has made the entire cannabis group toxic.

Have Those Once-Smoking Cannabis Stocks Burnt Down to a Bottom?

Several watchers and market players are deep in the weeds, tracking short action and key companies like Canopy Growth, trying to find out whether the industry has turned over a new leaf.

These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis

No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.

Johnson & Johnson Rises on $572 Million Fine That's Smaller Than Feared

Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Why Macy's Is at Risk of Losing Its Shirt

Earnings misses, bad planning, and product-line execution problems are all hitting the retailer, but it's the macro woes that will also hurt its competitors.

Earnings to Tell Whether Cannabis' High Growth Story Is Going to Pot

After a 2018 high, marijuana stocks are gaining popularity again, but which ones are producing the most green for investors? Here are the charts.

A Look at Mylan's New Post-Merger Management

What new management means for Mylan shareholders moving forward.

Mylan Jumps on Deal With Pfizer to Form New Company

Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.

Alphabet Shares Soar After Excellent Earnings Results

A big jump in the market cap of Google's parent is in store thanks to an impressive second-quarter report.